UNSPSC 51282706: Oritavancin

A type of lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.

UNSPSC 51282706 Oritavancin, a Commodity code, shows minimal alignment between its nominal scope—a specific antibiotic pharmaceutical—and the actual state and local procurement activity tagged under it. The recent opportunities solicited under this code involve naloxone, drug deactivation systems, general medical and first aid supplies for fire rescue operations, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing. None of these solicitations explicitly seek oritavancin or narrow-spectrum antibiotics; instead, they reflect broader state and local demand for emergency medical supplies, pharmacy benefit program management, and commoditized pharmaceutical inventory through established wholesaler networks. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (MMCAP), indicating that this code is being applied across diverse public-health and emergency-services procurement channels rather than to targeted antibiotic sourcing.

Geographic activity centers on Florida, Texas, and Minnesota through MMCAP's multistate membership. Recent opportunities include an IFB from Seminole County for naloxone and drug deactivation systems due July 26, 2023; an RFI from the Texas Health and Human Services Commission exploring direct-to-manufacturer pharmacy programs (response deadline April 3, 2026); an IFB from the City of Tampa for medical and first aid supplies with an estimated contract value of $700,000.00 and response deadline March 13, 2026; and an RFP from MMCAP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The code shows no recent activity directly soliciting oritavancin or indicating sustained demand under its stated pharmaceutical classification. Procurement professionals evaluating this code should recognize the mismatch and clarify the actual pharmaceutical or medical-supply categories their firm targets before pursuing opportunities tagged here.